Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TGN1412--a regulator's perspective.

× No keyword cloud information.

9 in total

1. From pharmacology to immunopharmacology.

Authors: Adam Cohen
Journal: Br J Clin Pharmacol Date: 2006-10 Impact factor: 4.335

2. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany.

Authors: Janice M Reichert
Journal: MAbs Date: 2011-05-01 Impact factor: 5.857

Review 3. Cytokines as biomarkers of nanoparticle immunotoxicity.

Authors: Mahmoud Elsabahy; Karen L Wooley
Journal: Chem Soc Rev Date: 2013-06-21 Impact factor: 54.564

Review 4. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors: Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2017-08-30 Impact factor: 8.110

5. Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation.

Authors: Paula C Soto; Lance L Stein; Nancy Hurtado-Ziola; Stephen M Hedrick; Ajit Varki
Journal: J Immunol Date: 2010-03-15 Impact factor: 5.422

6. Data Mining as a Guide for the Construction of Cross-Linked Nanoparticles with Low Immunotoxicity via Control of Polymer Chemistry and Supramolecular Assembly.

Authors: Mahmoud Elsabahy; Karen L Wooley
Journal: Acc Chem Res Date: 2015-05-26 Impact factor: 22.384

TGN1412--a regulator's perspective.

1. From pharmacology to immunopharmacology.

2. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany.

Review 3. Cytokines as biomarkers of nanoparticle immunotoxicity.

Review 4. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

5. Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation.

6. Data Mining as a Guide for the Construction of Cross-Linked Nanoparticles with Low Immunotoxicity via Control of Polymer Chemistry and Supramolecular Assembly.

7. Determinants of the establishment of human immunodeficiency virus type 1 latency.

8. Strengthening institutional review board review of highly innovative interventions in clinical trials.

Review 9. Regulatory T-Cells: Potential Regulator of Tissue Repair and Regeneration.